OncoBone Therapeutics develops novel therapies for bone metastasizing cancers
Osteoimmuno-oncology (OIO) refers to interactions of cancer, bone and immune cells, three compartments important in regulating growth of bone metastases. Efficacy of therapies is confirmed utilizing our preclinical Bone Metastasis Technology Platform©, followed by regulatory safety studies to complete IND-ready packages. The therapeutic assets are then outlicensed to larger pharma or biotech companies for clinical development.
Key Numbers
19 .3 m
New cancer cases globally in 2020, expected to increase to 28.6m by 2040
10 m
Cancer deaths globally in 2020
(one in six of all deaths), mainly caused by metastases
70-90%
Advanced stage breast and prostate cancer patients develop bone metastases
5 %
Patients with bone metastases alive five years after the diagnosis
(no effective treatments available)
270 bn
Cancer therapy market value in 2026, estimated to reach $447bn by 2031
Pipeline
The current pipeline of OncoBone Therapeutics includes three proprietary therapeutic assets and two therapeutic assets that are co-developed with original inventors of the assets.
Investors
OncoBone Therapeutics seeks investor funding for our drug development programs. The company expects to generate profitable business within three years after completing the next funding round, after which the company needs no further external funding and will be a target for profitable exit through IPO or trade sale.
News & Media
OncoBone Therapeutics nominates Theresa Guise and Paul Kostenuik as Advisors
OBP-004, a novel small-molecule dual inhibitor of CDK9/13, reduces bone, brain, lung and lymph node metastases in vivo, with highest potency on bone metastases
Tiina E. Kähkönen, Gergana Galabova, Ru Yang, Yuyang Xu, Jie Wen, Michael Thormann, Jussi M. Halleen2025